Approaches to knock down CNPY2 include the use of siRNA to inhibit CNPY2 in HCC cells [7], as well as miR-30a-3p, a potential therapeutic option to downregulate CNPY2 in NSCLC cells [54]. Here, CNPY2 is linked to hepatocellular carcinoma.